*Corresponding author. Tel: +34-922-318484; Fax: +34-922-318514; E-mail: jpinero@ull.es Sir, In southern Europe, leishmaniasis is an opportunistic infectious disease affecting patients treated with immunosuppressive agents or with the human immunodeficiency virus (HIV) infection, occurring in 2-7% of AIDS patients. 1 The number of cases of visceral leishmaniasis/HIV co-infection reported in Spain, France, Italy and Portugal between January 1996 and June 1998 represents 49.8% of the total number of cases these countries have reported since 1990. 2 In Spain, c. 100 human cases are reported each year, and there are thought to be a large number of undeclared cases. 3 Liposomal amphotericin B is an effective treatment for visceral leishmaniasis in immunocompetent adults and children, including those with severe or pentavalent antimonialresistant disease.
In Promastigotes were cultured in RPMI 1640 liquid medium (Gibco-BRL) with heat-inactivated fetal bovine serum. Parasites were added to sterilized microtitre plates with 24 wells (Corning) at a concentration of 5 × 10 4 /well (500 µL/well), exposed to drugs for 48 h and counted on a Coulter Counter model Z1. The 50% inhibitory concentration (IC 50 ) was determined by linear regression analysis with 95% confidence limits.
Tests were performed in at least triplicate on three different days in order to verify the results.
Intracellular amastigotes were cultured in the macrophage cell line J-774, in RPMI 1640 medium (Gibco-BRL) in 24-well (Corning) microtitre plates at a concentration of 50 000 cells/ well (500 µL/well), as described previously. 4 After macrophage infection, drug activity was evaluated by culture for 2 days at 37°C in humidified CO 2 /air (5%/95%). The percentage of infected cells was evaluated microscopically by counting at three distinct places in the well, and each assay was carried out in triplicate. The IC 50 was determined from infected cells versus log drug concentration.
These experiments showed that Abelcet has a higher leishmanicidal activity than Fungizone on promastigotes in all strains analysed (Table 1 ). The strains BCN-143 and BCN-167, Assays with the amastigote form also showed that Abelcet has higher leishmanicidal activity. In all cases the IC 50 values obtained were higher than those obtained in trials with promastigote forms of the parasite ( Table 1) .
The results of our study show that Fungizone is less effective than Abelcet in the macrophage J-774 model. The parasite's amastigote stage in all cases showed lower susceptibility to the compounds tested than did the promastigote stage.
The different activities observed in both in vitro studies were attributable to differences in size and composition of the particles and interaction with both lipoprotein and host cells by the amphotericin B formulations used in this study.
Previous results also suggest that variation in the activity of amphotericin B formulations against Leishmania in macrophage models are attributable, in part, to the type of macrophage model. Yardley & Croft 6 showed that Abelcet and Amphocil were the most active formulations in the THP-1 Leishmania donovani model, with Fungizone and AmBisome having lower activity, albeit similar in nature. In the same study, in a model using peritoneal macrophages from CD1 mice, Fungizone was more active than Abelcet. In our study a similar pattern was observed in the THP-1 L. donovani model, where Abelcet was c. 7-to 15-fold more active than Fungizone.
